上海医药
(601607)
| 流通市值：349.80亿 | | | 总市值：670.67亿 |
| 流通股本：19.32亿 | | | 总股本：37.03亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 70,152,787,484.98 | 260,295,088,943.53 | 197,508,314,193.06 | 132,592,157,323.37 |
| 营业收入 | 70,152,787,484.98 | 260,295,088,943.53 | 197,508,314,193.06 | 132,592,157,323.37 |
| 二、营业总成本 | 67,891,869,133.58 | 253,008,863,712.03 | 191,379,813,519.61 | 128,205,807,529.43 |
| 营业成本 | 62,124,770,085.55 | 228,966,947,001.24 | 173,545,899,008.19 | 115,533,492,130.9 |
| 税金及附加 | 208,543,989.33 | 738,106,426.32 | 548,357,726.47 | 377,172,900.67 |
| 销售费用 | 3,291,277,261.72 | 13,902,191,503.5 | 10,470,048,801.68 | 7,732,875,492.74 |
| 管理费用 | 1,391,396,718.62 | 5,711,827,446.09 | 4,193,117,737.88 | 2,762,737,366.79 |
| 研发费用 | 501,451,930.27 | 2,204,033,687.43 | 1,468,042,692.55 | 1,026,309,891.55 |
| 财务费用 | 374,429,148.09 | 1,485,757,647.45 | 1,154,347,552.84 | 773,219,746.78 |
| 其中:利息费用 | 471,671,030.51 | 1,884,984,092.73 | 1,461,288,526.07 | 962,461,260.78 |
| 其中:利息收入 | 136,280,254.05 | -461,833,287.29 | 356,739,560 | -212,569,528.64 |
| 加:公允价值变动收益 | 52,252,233.13 | 404,731,380.72 | 239,023,469.04 | 196,842,384.45 |
| 加:投资收益 | 166,442,382.22 | -68,122,676.68 | -83,824,385.72 | -198,992,363.96 |
| 资产处置收益 | 110,037,311.32 | 92,475,307.03 | 104,578,571.48 | 73,745,726.6 |
| 资产减值损失(新) | 27,224,797.01 | -561,277,474.11 | 33,913,101.75 | 66,099,386.5 |
| 信用减值损失(新) | -269,024,743.68 | -279,958,650.49 | -296,512,481.18 | -336,316,422.58 |
| 其他收益 | 66,831,919.34 | 793,161,586.35 | 430,276,148.13 | 370,355,726.92 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,414,682,250.74 | 7,667,234,704.32 | 6,555,955,096.95 | 4,558,084,231.87 |
| 加:营业外收入 | 14,499,195.52 | 40,689,731.27 | 27,508,032.42 | 18,105,606.98 |
| 减:营业外支出 | 12,481,130.01 | 653,627,697.11 | 64,467,953.42 | 42,397,333.46 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,416,700,316.25 | 7,054,296,738.48 | 6,518,995,175.95 | 4,533,792,505.39 |
| 减:所得税费用 | 551,127,979.96 | 1,887,726,454.22 | 1,565,226,954.19 | 1,116,791,485.41 |
| 六、净利润 | 1,865,572,336.29 | 5,166,570,284.26 | 4,953,768,221.76 | 3,417,001,019.98 |
| 持续经营净利润 | 1,865,572,336.29 | 5,166,570,284.26 | 4,953,768,221.76 | 3,417,001,019.98 |
| 归属于母公司股东的净利润 | 1,542,277,554.18 | 3,767,999,581.18 | 3,796,770,660.15 | 2,609,821,842.28 |
| 少数股东损益 | 323,294,782.11 | 1,398,570,703.08 | 1,156,997,561.61 | 807,179,177.7 |
| (一)基本每股收益 | 0.42 | 1.02 | 1.03 | 0.71 |
| (二)稀释每股收益 | 0.42 | 1.02 | 1.03 | 0.71 |
| 八、其他综合收益 | 463,240.42 | -126,719,890.54 | -170,966,425.38 | -122,849,260.45 |
| 归属于母公司股东的其他综合收益 | -4,913,166.7 | -124,765,766.2 | -167,435,398.49 | -126,917,246.5 |
| 九、综合收益总额 | 1,866,035,576.71 | 5,039,850,393.72 | 4,782,801,796.38 | 3,294,151,759.53 |
| 归属于母公司股东的综合收益总额 | 1,537,364,387.48 | 3,643,233,814.98 | 3,629,335,261.66 | 2,482,904,595.78 |
| 归属于少数股东的综合收益总额 | 328,671,189.23 | 1,396,616,578.74 | 1,153,466,534.72 | 811,247,163.75 |
| 公告日期 | 2024-04-27 | 2024-03-29 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |